Grapiprant is under clinical development by Ikena Oncology and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase I drugs for Colorectal Cancer have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Grapiprant’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Grapiprant overview

Grapiprant (RQ-0000007, RQ-7, MR10A7) is under development for the treatment of hepatocellular carcinoma, triple negative/inflammatory breast cancer, non small cell lung cancer, cancer pain, osteoarthritis pain,metastatic colorectal cancer, esophageal cancer, gastric cancer, head and neck cancer, chronic pain, osteoarthritis pain, post-operative pain, tumors including liver cancer, colorectal cancer, breast cancer, non-small cell lung cancer adenocarcinoma and gastroenterological cancer, autoimmune disorders and allergies. It is administered intravenously and orally. RQ-0000007 (MR10A7) acts by targeting EP4 receptor.

It was also under development for the treatment of non-small cell lung cancer.

Ikena Oncology overview

Ikena Oncology is a clinical-stage biotechnology company that discovers and develops novel cancer therapies. Its pipeline products include IK-930, IK-595 and IK-175. The company’s pipeline treats hippo-altered cancers, RAS (Rat Sarcoma) mutated cancers and bladder cancer. Ikena Oncology targeted program carries out in hippo and RAS (Rat Sarcoma) such as IK-930 TEAD inhibitor and IK-595: MEK-CRAF inhibition. Its immune signal targeting programs in tumor microenvironment modulation (TME) such as AHR inhibition and IK-175: AHR antagonist. The company’s program is built on robust translational research. Ikena Oncology is headquartered in Boston, Massachusetts, the US.

For a complete picture of Grapiprant’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 22 April 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.